Smith, Michael A <br/><br/>
Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.  [electronic resource] 

 -  The Annals of pharmacotherapy  Dec 2014 
 - 1629-35 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1542-6270 
<br/><br/><label>Standard No.: </label>10.1177/1060028014549799  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Clinical Trials, Phase I as Topic<br/>Clinical Trials, Phase II as Topic<br/>Clinical Trials, Phase III as Topic<br/>Colitis, Ulcerative--drug therapy<br/>Crohn Disease--drug therapy<br/>Humans<br/>Inflammatory Bowel Diseases--drug therapy<br/>Integrins--antagonists & inhibitors<br/>Male